OBI Pharma adopts the considerations outlined in the GRI Standards as the basis for identifying sustainability issues. Following the four-step materiality assessment process under the GRI Standards 2021, issues were evaluated against two key indicators: the level of stakeholder concern and the degree of impact, with those exceeding the mid-point threshold regarded as material topics.
The Company conducted surveys to understand which topics stakeholders care about and the extent to which each topic impacts them. In parallel, senior management assessed the potential and actual impacts of each topic on the Company, as well as on the external economy, environment, and society.
In 2024, through this process, 30 sustainability issues were compiled. These were reviewed, analyzed, and validated through internal meetings and departmental reviews with relevant stakeholder counterparts, leading to the identification of material topics. Looking ahead, OBI Pharma will continue to adhere to this principle, maintain ongoing communication with stakeholders, and review material topics annually to ensure that the sustainability report accurately reflects the impact and scope of material issues on both stakeholders and the Company.
Analysis of Material Topics
After cross-analyzing stakeholder “concern on issues” and the “significance of operational impact,” OBI Pharma identified 12 material topics in 2024: innovation and R&D, stakeholder engagement, talent recruitment and retention, corporate governance, financial performance, risk management, labor relations, occupational health and safety, career development and training, employee compensation and benefits, ethical conduct and code of practice, and information security.
For these material topics, the Company has collected and disclosed in this report key information and performance indicators that align with stakeholder concerns in 2024. OBI Pharma will continue to strengthen management in these areas moving forward.
Boundaries of Material Topics
OBI Pharma approaches its sustainability assessment from the perspective of the value chain, analyzing the impact scope of each material topic. This enables the Company to understand the degree of interaction between material topics and the value chain while also identifying areas that require further strengthening. Looking ahead, OBI Pharma aims to expand its value chain analysis comprehensively to enhance corporate value and mitigate risks and negative impacts.
As all of OBI Pharma’s products are currently in the R&D stage and not yet commercialized, the Company evaluates its value chain based on the structure of the biotechnology drug development industry. OBI Pharma’s core operations focus on new drug research and development, with the upstream involving drug composition determination and the downstream encompassing clinical trials. The stakeholders impacted along the value chain are categorized into six groups: upstream—suppliers, research partners, and government; operations—OBI Pharma, investors, and employees; downstream—contracted organizations.